Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.

Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E.

Osteoporos Int. 2013 Sep;24(9):2499-507. doi: 10.1007/s00198-013-2325-6. Epub 2013 Mar 23.

PMID:
23525894
2.

Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial.

Emaus N, Gjesdal CG, Almås B, Christensen M, Grimsgaard AS, Berntsen GK, Salomonsen L, Fønnebø V.

Osteoporos Int. 2010 Oct;21(10):1731-40. doi: 10.1007/s00198-009-1126-4. Epub 2009 Nov 25.

PMID:
19937427
3.

Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women.

Knapen MH, Schurgers LJ, Vermeer C.

Osteoporos Int. 2007 Jul;18(7):963-72. Epub 2007 Feb 8.

4.

Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects.

Theuwissen E, Cranenburg EC, Knapen MH, Magdeleyns EJ, Teunissen KJ, Schurgers LJ, Smit E, Vermeer C.

Br J Nutr. 2012 Nov 14;108(9):1652-7. doi: 10.1017/S0007114511007185. Epub 2012 Jan 31.

PMID:
22289649
5.

Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.

Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R.

PLoS Med. 2008 Oct 14;5(10):e196. doi: 10.1371/journal.pmed.0050196. Erratum in: PLoS Med. 2008 Dec;5(12):e247.

6.

Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women.

Koitaya N, Ezaki J, Nishimuta M, Yamauchi J, Hashizume E, Morishita K, Miyachi M, Sasaki S, Ishimi Y.

J Nutr Sci Vitaminol (Tokyo). 2009 Feb;55(1):15-21.

7.

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.

Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY.

Osteoporos Int. 2009 Oct;20(10):1663-73. doi: 10.1007/s00198-008-0825-6. Epub 2009 Jan 20.

8.

The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.

Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, Yao X, Gu G, Hao Y, Li Z, Zhao Y, Li W, Yang J, Zhao X, Shi D, Fuerst T, Lu Y, Li H, Zhang X, Li C, Zhao J, Wu Q, Zhao SJ.

Osteoporos Int. 2012 Apr;23(4):1317-27. doi: 10.1007/s00198-011-1577-2. Epub 2011 Apr 20.

PMID:
21505910
9.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.

JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. Erratum in: JAMA. 2017 Jan 24;317(4):442.

PMID:
27533157
10.

The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children.

van Summeren MJ, Braam LA, Lilien MR, Schurgers LJ, Kuis W, Vermeer C.

Br J Nutr. 2009 Oct;102(8):1171-8. doi: 10.1017/S0007114509382100. Epub 2009 May 19.

PMID:
19450370
11.

Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.

Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.

Osteoporos Int. 2014 Apr;25(4):1401-10. doi: 10.1007/s00198-014-2619-3. Epub 2014 Feb 8.

PMID:
24510095
12.

Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.

Koitaya N, Sekiguchi M, Tousen Y, Nishide Y, Morita A, Yamauchi J, Gando Y, Miyachi M, Aoki M, Komatsu M, Watanabe F, Morishita K, Ishimi Y.

J Bone Miner Metab. 2014 Mar;32(2):142-50. doi: 10.1007/s00774-013-0472-7. Epub 2013 May 24.

PMID:
23702931
13.

A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.

Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP 2nd, Rosenberg E, Denker AE.

Osteoporos Int. 2016 Jan;27(1):377-86. doi: 10.1007/s00198-015-3392-7. Epub 2015 Nov 10.

PMID:
26556736
14.

Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.

Palomba S, Orio F Jr, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.

Osteoporos Int. 2005 Sep;16(9):1141-9. Epub 2005 Jun 1.

PMID:
15928801
15.

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.

Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, Diaz-Curiel M, Brandi ML, Badurski J, Wark J, Balogh A, Bruyère O, Roux C.

Osteoporos Int. 2012 Mar;23(3):1115-22. doi: 10.1007/s00198-011-1847-z. Epub 2011 Nov 29.

16.

Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.

Binkley N, Bone H, Gilligan JP, Krause DS.

Osteoporos Int. 2014 Nov;25(11):2649-56. doi: 10.1007/s00198-014-2796-0. Epub 2014 Jul 16.

17.

Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women.

Rønn SH, Harsløf T, Pedersen SB, Langdahl BL.

Eur J Endocrinol. 2016 Dec;175(6):541-549. Epub 2016 Sep 13.

18.

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.

Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S.

Osteoporos Int. 2014 Jan;25(1):367-76. doi: 10.1007/s00198-013-2398-2. Epub 2013 May 29.

PMID:
23716037
19.

Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.

Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K, Ishikawa Y, Saito H, Chida S, Shimada Y.

J Bone Miner Metab. 2014 May;32(3):290-7. doi: 10.1007/s00774-013-0490-5. Epub 2013 Jul 12.

PMID:
23846118
20.

Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.

Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, Ma KM.

Ann Rheum Dis. 2011 May;70(5):778-84. doi: 10.1136/ard.2010.143453. Epub 2010 Dec 27.

PMID:
21187295

Supplemental Content

Support Center